Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines, Inc. (PBLS) is a healthcare company (biotechnology) based in the United States. The share price is $28.08, down 1.30% on the day, which values the company at $3.52B. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$28.08−1.30% today
Market value
$3.52B
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Parabilis Medicines, Inc. in more detail

PBLS trades at -12.0× next year's expected earnings, 1554.9× sales.

Worth checking: Weak Piotroski score; Thin interest cover.

3 of the superinvestors tracked here hold PBLS, including Peter Kolchinsky (6.9% of the portfolio), Andrew Spokes (0.4% of the portfolio), Julian and Felix Baker (0.1% of the portfolio).

Superinvestors holding PBLS

3 of the investors tracked here report a position in their latest 13F filing.

Parabilis Medicines, Inc. (PBLS): questions and answers

What is Parabilis Medicines, Inc.'s market cap?

Parabilis Medicines, Inc. is valued at $3.52B at a share price of $28.08.

Does PBLS pay a dividend?

Parabilis Medicines, Inc. does not currently pay a regular dividend.

Which famous investors own PBLS?

In their latest quarterly filings, Peter Kolchinsky (6.9% of the portfolio), Andrew Spokes (0.4% of the portfolio), Julian and Felix Baker (0.1% of the portfolio) hold PBLS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Parabilis Medicines, Inc. (PBLS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/PBLS

Underlying data: Yahoo Finance; company filings with the SEC.